Hennion & Walsh Asset Management Inc. Buys 10,799 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Hennion & Walsh Asset Management Inc. raised its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 14.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 85,871 shares of the company's stock after purchasing an additional 10,799 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.15% of Harmony Biosciences worth $2,850,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HRMY. Barclays PLC increased its stake in Harmony Biosciences by 110.9% in the third quarter. Barclays PLC now owns 76,862 shares of the company's stock valued at $3,074,000 after purchasing an additional 40,416 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of Harmony Biosciences by 9.8% during the fourth quarter. Janney Montgomery Scott LLC now owns 17,445 shares of the company's stock worth $600,000 after acquiring an additional 1,550 shares in the last quarter. KBC Group NV increased its position in shares of Harmony Biosciences by 79.9% during the fourth quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after acquiring an additional 819 shares in the last quarter. Yousif Capital Management LLC increased its position in shares of Harmony Biosciences by 22.4% during the fourth quarter. Yousif Capital Management LLC now owns 14,325 shares of the company's stock worth $493,000 after acquiring an additional 2,622 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its position in shares of Harmony Biosciences by 26.3% during the fourth quarter. State of Alaska Department of Revenue now owns 21,716 shares of the company's stock worth $747,000 after acquiring an additional 4,526 shares in the last quarter. 86.23% of the stock is owned by institutional investors.

Harmony Biosciences Stock Up 1.6%

HRMY stock traded up $0.57 during trading on Friday, reaching $35.60. The stock had a trading volume of 441,103 shares, compared to its average volume of 616,941. Harmony Biosciences Holdings, Inc. has a one year low of $26.47 and a one year high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The company's 50 day moving average is $31.77 and its two-hundred day moving average is $34.07. The company has a market capitalization of $2.04 billion, a price-to-earnings ratio of 16.87, a P/E/G ratio of 0.47 and a beta of 0.87.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. During the same period in the prior year, the firm posted $0.67 EPS. The firm's quarterly revenue was up 19.5% compared to the same quarter last year. Equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Mizuho boosted their target price on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a research report on Thursday, May 15th. Cantor Fitzgerald raised shares of Harmony Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. UBS Group decreased their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Monday, April 28th. Needham & Company LLC reissued a "buy" rating and set a $49.00 target price on shares of Harmony Biosciences in a research report on Tuesday, May 6th. Finally, Oppenheimer assumed coverage on shares of Harmony Biosciences in a research report on Monday, June 2nd. They set an "outperform" rating and a $61.00 target price for the company. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $53.00.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.